Tuvusertib

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

1 Completed trials

3 Sponsors

8 Countries

Phase II

Phase I/II

Phase II: 2 Phase I/II: 1

Oversight events:

5 temporary halts across 1 trial

View oversight register →

Indications tested

Sponsors using this IMP

Grupo Espanol De Investigacion En Neurooncologia 1 Institut Paoli Calmettes 1 Merck Healthcare KGaA 1

All trials

3 total

MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors… Recruiting

2023-507485-10-00 Phase I/II 1 country Institut Paoli-Calmettes
Efficacy of Tuvusertib in Recurrent IDH mutant Astrocytoma with ATRX mutation, a phase II prospective trial. Recruiting

2025-521843-19-00 Phase II 1 country Grupo Espanol De Investigacion En Neurooncologia
Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended

2024-511202-23-00 Phase II 8 countries Merck Healthcare KGaA

Showing 1–3 of 3 trials

← All drugs A–Z